We studied the effects of birinapant, a mimetic of the second mitochondria-derived activator of caspase (SMAC), on invasion and proliferation of MGC-803 gastric cancer cells and the molecular mechanisms underlying these processes. The expression of cellular inhibitor of apoptosis 1 (cIAP1) and TNF receptor-associated factor 3 (TRAF3) in gastric cancer cell line MGC-803 and normal gastric mucosa GES-1 cells were analyzed by Western blotting and cell immunofluorescence assay. After pretreatment of MGC-803 cells with birinapant, a Transwell invasion assay was used to evaluate the cell invasion ability. MGC-803 cells were implanted under the skin of BALB/c nude mice. The tumors were removed 10 days later and its size was measured. Protein expression of proliferating cell nuclear antigen (PCNA) in the subcutaneous tumors was analyzed by immunohistochemical method. In addition, the expression of cIAP1, TRAF3, pNF-κB, and NF-κB in control and birinapant-treated cells was compared by Western blotting and the rate of cell apoptosis was evaluated by flow cytometry. In untreated MGC-803 gastric cancer cells, the expression of cIAP1 was higher and the expression of TRAF3 was lower than in normal gastric mucosa cell line GES-1. Pretreatment with birinapant inhibited the invasion and proliferation of MGC-803 cells and promoted cell apoptosis. Birinapant also promoted the expression of TRAF3 and inhibited the expression of cIAP1 and pNF-κB in MGC-803 cells. Thus, birinapant inhibited the expression of cIAP1, prevented degradation of TRAF3, and suppressed invasion and proliferation of MGC-803 cells by promoting cell apoptosis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cossu F, Milani M, Mastrangelo E, Lecis D. Targeting the BIR Domains of Inhibitor of Apoptosis (IAP) Proteins in Cancer Treatment. Comput. Struct. Biotechnol J. 2019;17:142-150. doi: https://doi.org/10.1016/j.csbj.2019.01.009
Digklia A, Wagner AD. Advanced gastric cancer: Current treatment landscape and future perspectives. World J. Gastroenterol. 2016;22(8):2403-2414. doi: https://doi.org/10.3748/wjg.v22.i8.2403
Fu DG. Epigenetic alterations in gastric cancer (Review). Mol. Med. Rep. 2015;12(3):3223-3230. doi: https://doi.org/10.3892/mmr.2015.3816
Fulda S. Promises and Challenges of Smac Mimetics as Cancer Therapeutics. Clin. Cancer Res. 2015;21(22):5030-5036. doi: https://doi.org/10.1158/1078-0432.CCR-15-0365
Kearney CJ, Lalaoui N, Freeman AJ, Ramsbottom KM, Silke J, Oliaro J. PD-L1 and IAPs co-operate to protect tumors from cytotoxic lymphocyte-derived TNF. Cell Death Differ. 2017;24(10):1705-1716. doi: https://doi.org/10.1038/cdd.2017.94
Li H, Fang Y, Niu C, Cao H, Mi T, Zhu H, Yuan J, Zhu J. Inhibition of cIAP1 as a strategy for targeting c-MYC-driven oncogenic activity. Proc. Natl Acad. Sci. USA. 2018;115(40):E9317-E9324. doi: https://doi.org/10.1073/pnas.1807711115
Liu H, Liao R, He K, Zhu X, Li P, Gong J. The SMAC mimetic birinapant attenuates lipopolysaccharide-induced liver injury by inhibiting the tumor necrosis factor receptor-associated factor 3 degradation in Kupffer cells. Immunol. Lett. 2017;185:79-83. doi: https://doi.org/10.1016/j.imlet.2017.02.016
Ma Y, Liu W, Li J, Xu Y, Wang H. Gastric cancer with breast metastasis: Clinical features and prognostic factors. Oncol. Lett. 2018;16(5):5565-5574. doi: https://doi.org/10.3892/ol.2018.9383
Pluta P, Jesionek-Kupnicka D, Kubicka-Wołkowska J, Pluta A, Brzozowski K, Potemski P, Piekarski J, Kordek R, Jeziorski A. SMAC protein expression as a potent favorable prognostic factor in locally advanced breast cancer. Pol. J. Pathol. 2018;69(1):33-41. doi: https://doi.org/10.5114/pjp.2018.75334
Rathore R, McCallum JE, Varghese E, Florea AM, Büsselberg D. Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs). Apoptosis. 2017;22(7):898-919. doi: https://doi.org/10.1007/s10495-017-1375-1
Wang L, Ouyang F, Liu X, Wu S, Wu HM, Xu Y, Wang B, Zhu J, Xu X, Zhang L. Overexpressed CISD2 has prognostic value in human gastric cancer and promotes gastric cancer cell proliferation and tumorigenesis via AKT signaling pathway. Oncotarget. 2016;7(4):3791-3805. doi: https://doi.org/10.18632/oncotarget.6302
Wang W, Liu J, Qi J, Zhang J, Zhu Q, Qin C. RLIP76 increases apoptosis through Akt/mTOR signaling pathway in gastric cancer. Oncol. Rep. 2016;36(4):2216-2224. doi: https://doi.org/10.3892/or.2016.5043
Wu X, Tao P, Zhou Q, Li J, Yu Z, Wang X, Li J, Li C, Yan M, Zhu Z, Liu B, Su L. IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway. Oncotarget. 2017;8(13):20 741-20 750. doi: https://doi.org/10.18632/oncotarget.15119
Yi Z, Wallis AM, Bishop GA. Roles of TRAF3 in T cells: many surprises. Cell Cycle. 2015;14(8):1156-1163. doi: https://doi.org/10.1080/15384101.2015.1021524
Zhou L, Zhang Y, Leng Y, Dai Y, Kmieciak M, Kramer L, Sharma K, Wang Y, Craun W, Grant S. The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo. J. Hematol. Oncol. 2019;12(1):25. doi: https://doi.org/10.1186/s13045-019-0713-x
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 171, No. 1, pp. 73-79, January, 2021
Rights and permissions
About this article
Cite this article
Zhu, D.L., Shuai, L.Y. Effects of Birinapant on Proliferation and Invasion of MGC-803 Gastric Cancer Cells and Mechanism Underlying These Effects. Bull Exp Biol Med 171, 56–61 (2021). https://doi.org/10.1007/s10517-021-05172-w
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-021-05172-w